Welcome to our dedicated page for Crescent Biopharma SEC filings (Ticker: cbio), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial updates, milestone payments, and cash runway projections for Catalyst Biosciences, Inc. (CBIO) are buried across hundreds of SEC pages. Every 10-K dissects protease-based pipeline data, and each 8-K may reveal trial results that can move the share price overnight. For investors tracking a pre-revenue biotech, missing one sentence on convertible equity or FDA feedback can be costly. That’s why finding Catalyst Biosciences insider trading Form 4 transactions or sifting through a Catalyst Biosciences quarterly earnings report 10-Q filing often feels like decoding lab notes.
Stock Titan solves this research bottleneck. Our AI reads every submission the moment it hits EDGAR, delivering Catalyst Biosciences SEC filings explained simply. Need the latest Catalyst Biosciences Form 4 insider transactions real-time? You’ll receive instant alerts. Curious about cash burn trends? Our dashboard links the numbers inside a Catalyst Biosciences earnings report filing analysis to previous quarters. We even flag dilution risks hidden in shelf registrations and translate risk-factor language, so understanding Catalyst Biosciences SEC documents with AI becomes effortless.
Whether you’re checking a Catalyst Biosciences annual report 10-K simplified for R&D expenses, comparing a Catalyst Biosciences proxy statement executive compensation to peers, or reviewing Catalyst Biosciences 8-K material events explained after a trial update, every disclosure is organized in one place. Track Catalyst Biosciences executive stock transactions Form 4, monitor option grants, and see real-time updates without opening a single PDF. Save hours, stay ahead of market-moving biotech news, and make decisions with clarity.
Crescent Biopharma’s Chief Scientific Officer reports new equity grants. On December 15, 2025, the officer acquired 17,507 and 5,000 Ordinary Shares, for a total of 22,507 Ordinary Shares beneficially owned directly after the transactions.
The filing also discloses a stock option grant for 70,025 Ordinary Shares at an exercise price of $13.21 per share, expiring on December 15, 2035. These options vest in 1/48th monthly installments from December 15, 2025, while the related Restricted Stock Units vest in approximately equal three‑month installments over four years, in each case contingent on continued service.
Crescent Biopharma, Inc. reported new equity awards to its Chief Business Officer, Christopher Doughty. On December 15, 2025, he acquired 14,714 and 8,000 ordinary shares through awards of restricted stock units (RSUs). Each RSU represents a right to receive one ordinary share, vesting in roughly equal three‑month installments over four years from December 15, 2025, as long as he continues to work for the company or its subsidiaries.
On the same date, Doughty also received a stock option covering 58,855 ordinary shares at an exercise price of
Crescent Biopharma, Inc. reported new equity awards to its Chief Executive Officer and director, Joshua T. Brumm, as of December 15, 2025. He acquired 45,117 Ordinary Shares and an additional 10,000 Ordinary Shares, bringing his total beneficial ownership to 323,517 Ordinary Shares held directly.
Brumm also received a stock option giving him the right to buy 180,467 Ordinary Shares at an exercise price of $13.21 per share, expiring on December 15, 2035. The option vests in equal monthly installments of 1/48th each month starting from December 15, 2025, while the related Restricted Stock Units vest in approximately equal three‑month installments over four years from that same date, in each case conditioned on his continued service to Crescent Biopharma or its subsidiaries.
Crescent Biopharma, Inc. reported an equity compensation grant to its Chief Financial Officer, who is an officer and reporting person of the company. On December 15, 2025, the officer received 14,422 Ordinary Shares in the form of Restricted Stock Units (RSUs), each representing the right to receive one Ordinary Share as they vest. The RSUs are scheduled to vest in approximately equal three‑month installments over four years from December 15, 2025, conditioned on continued service.
On the same date, the officer was also granted a stock option to purchase 57,688 Ordinary Shares at an exercise price of $13.21 per share, expiring on December 15, 2035. This option vests as to 1/48th of the option on each monthly anniversary of December 15, 2025, also subject to continued employment or service with Crescent Biopharma or its subsidiaries.
Crescent Biopharma, Inc. reported an insider equity grant for its President and COO, Jonathan McNeill. On December 15, 2025, he acquired 19,507 and 6,000 Ordinary Shares as awards of restricted stock units (RSUs), and now directly beneficially owns 159,707 Ordinary Shares.
The RSUs each represent a right to receive one Ordinary Share and will vest in approximately equal three-month installments over four years from December 15, 2025, contingent on continued service. He also received a stock option for 78,029 Ordinary Shares at an exercise price of $13.21 per share, expiring on December 15, 2035. This option vests as to 1/48th of the grant on each monthly anniversary of December 15, 2025, subject to continued employment or service.
Crescent Biopharma, Inc. reported new equity awards to its Chief Medical Officer, Ellie Im. On December 15, 2025, she acquired a total of 21,298 Ordinary Shares in the form of Restricted Stock Units (RSUs), shown as two grants of 16,298 and 5,000 shares. Each RSU represents a contingent right to receive one Ordinary Share, vesting in approximately equal three-month installments over four years from December 15, 2025, as long as she continues to work for the company or its subsidiaries.
She also received a stock option covering 65,190 Ordinary Shares at an exercise price of $13.21 per share. This option vests as to 1/48th of the grant on each monthly anniversary of December 15, 2025, subject to continued service, and is exercisable until December 15, 2035.
Crescent Biopharma, Inc. reported new equity awards to officer Ryan Lynch, who serves as Treasurer, Senior Vice President of Finance and Chief Accounting Officer. On December 15, 2025, Lynch acquired 8,378 Ordinary Shares and an additional 4,000 Ordinary Shares through awards of Restricted Stock Units (RSUs), bringing his directly held Ordinary Shares to 12,378.
Each RSU represents a contingent right to receive one Ordinary Share, vesting in approximately equal three‑month installments through the four‑year anniversary of December 15, 2025, contingent on continued service. Lynch also received a stock option for 33,512 Ordinary Shares at an exercise price of $13.21 per share, exercisable until December 15, 2035. This option vests as to 1/48th of the grant on each monthly anniversary of December 15, 2025, also conditioned on continuous employment or service.
Crescent Biopharma, Inc. reported an equity compensation grant to an executive officer. On December 15, 2025, the reporting person received 12,422 Ordinary Shares and an additional 6,000 Ordinary Shares as Restricted Stock Units, bringing their beneficial ownership to 18,422 Ordinary Shares. The RSUs vest in approximately equal three‑month installments over four years from December 15, 2025, contingent on continued service.
The officer was also granted a stock option for 72,185 Ordinary Shares at an exercise price of $13.21 per share, exercisable until December 15, 2035. This option vests as to 1/48th of the grant on each monthly anniversary of December 15, 2025, as long as the officer remains employed by or provides services to Crescent Biopharma or its subsidiaries.
Crescent Biopharma, Inc. filed a Form S-8 to register ordinary shares for equity compensation plans following its merger and redomiciliation. The filing covers 2,345,962 shares under the 2025 Stock Incentive Plan, 195,497 shares under the 2025 Employee Stock Purchase Plan, 3,684,330 shares under the 2024 Equity Incentive Plan (for assumed options from the merger), and 1,250,000 shares under the 2025 Employment Inducement Incentive Award Plan.
The company completed a business combination with Crescent Biopharma Operating Company on June 13, 2025 and, on June 16, 2025, changed its jurisdiction of incorporation to the Cayman Islands. The filing also details director and officer indemnification provisions consistent with Cayman law and lists the relevant plan documents and consents as exhibits.
Crescent Biopharma (CBIO) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $24.6 million for the quarter and $61.5 million year‑to‑date, driven primarily by research and development of preclinical oncology programs.
Cash and cash equivalents were $133.3 million as of September 30, 2025, and management expects this balance to fund operations for at least twelve months from the financial statement issuance date. Operating cash outflow was $44.8 million for the nine months. R&D expense was $20.3 million in Q3 ($43.1 million YTD); G&A was $5.5 million in Q3 ($18.1 million YTD).
During 2025 the company completed a reverse recapitalization with GlycoMimetics, raised capital via a pre‑closing financing, converted $37.5 million of convertible notes into equity, and redomesticated to the Cayman Islands. Shareholders’ equity improved to $116.6 million from a deficit at year‑end 2024. Ordinary shares outstanding were 13,892,516 as of November 3, 2025.
FAQ
What is the current stock price of Crescent Biopharma (cbio)?
What is the market cap of Crescent Biopharma (cbio)?
